Diagnostic Efficacy of grey-zone Serum Prostate Specific Antigen level in patients with Benign Prostatic Hyperplasia and Prostate Carcinoma
DOI:
https://doi.org/10.51985/JBUMDC2024431Keywords:
Benign Prostatic Hyperplasia; BPH; Grey zone PSA; Prostate specific antigen; Prostate carcinoma; Serum PSAAbstract
Objective: Evaluation of diagnostic role of grey zone serum prostate specific antigen level(4-10ng/ml) in patients with benign prostatic hyperplasia (BPH) and prostate carcinoma keeping histopathology as gold standard. Study design and setting: Cross-sectional study conducted in department of urology and chemical pathology, sheikh Zayed hospital Rahim yar khan.
Methodology: Patients with grey zone serum prostate specific antigen level (4-10ng/ml), lower urinary tract symptoms or abnormal DRE (digital rectal examination) were included and diagnosis was confirmed on the basis of histopathology. Chi square test used to see the statistically significant difference between subgroups. P value <0.05 was deemed as significant. Diagnostic role evaluated by ROC curve analysis.
Results: Mean age of study subjects was 60.21±10.046 years and 155 (81.2%) subjects were having serum prostate specific antigen level in grey zone (4-10ng/ml). Of the total 191 study subjects, 59(30.9%) were histopathologically confirmed cases of benign prostatic hyperplasia and 34(17.8%) were confirmed cases of prostate carcinoma. 41 (26.45%) cases of benign prostatic hyperplasia were having serum PSA level in grey zone (4-10ng/ml) and 16(10.32%) cases with prostate carcinoma were having PSA level in grey zone (4-10ng /ml). ROC curve analysis shows AUC=0.584 in case of BPH and AUC=0.707 in case of CA prostate.
Conclusion: On the basis of our study, it is concluded that grey zone serum PSA level in symptomatic individuals should be used in conjunction with other non-invasive diagnostic and clinical parameters to improve diagnosis and to avoid unnecessary biopsy in every symptomatic individual
References
1. Antony T, Talwar R, Thomas T, Trehan V, Manwatkar S,
Mohan H, et al. Correlation of serum prostate specific antigen
with clinical, radiological and pathological variables in
patients with prostate enlargement. Int Surg J 2019; 6:4408-
14. DOI: https://doi.org/10.18203/2349-2902.isj20195403
2. Cary K. C, & Cooperberg M. R. Biomarkers in prostate
cancer surveillance and screening: past, present, and future.
Therapeutic advances in urology, 2013;5(6): 318-329. doi:
10.1177/1756287213495915
3. Atif Hussain, S.., & Tumrani, R. (2022). Correlation between
Pre-Biopsy Serum Prostate Specific Antigen Level and Gleason
Score in Patients Diagnosed with Prostate Adenocarcinoma:
A Hospital Based Study: Pakistan Journal of Health Sciences,
2022; 3(07): https://doi.org/10.54393/pjhs.v3i07.404
4. O’Shaughnessy M, Konety B, Warlick C. Prostate cancer
screening: issues and controversies. Minnesota medicine,
2010; 93(8):39-44
5. Elshahmi E, Emaetig F, Elgaraboli F, Abushnaf A, Alqawi O.
The Evaluation of PSA levels in Libya Prostate Cancer Patients.
Clinical Oncology Research and Reports. 2022; 3(1): DOI:
10.31579/2693-4787/029
6. Li, X., Li, C. and Chen, M. (2023), Patients With “Gray Zone”
PSA Levels: Application of Prostate MRI and MRS in the
Diagnosis of Prostate Cancer. J Magn Reson Imaging, 57:
992-1010. https://doi.org/10.1002/jmri.28505
7. Lu YF, Zhang Q, Chen HY, Chen JY, Pan Y, Xu CC, Xu JX,
Yu RS. Improving the detection rate of prostate cancer in the
gray zone of PI-RADS v2 and serum tPSA by using prostatespecific antigen-age volume. Medicine (Baltimore).
2019;98(26): e16289. doi: 10.1097/MD.0000000000016289.
8. Guo Z-F, Yang F, Lu X-W, Wu J-W, He C, Han C-H.
Significance of the prostate central gland and total gland
volume ratio in the diagnosis of prostate cancer patients in
the prostate specific antigen grey zone. Journal of International
Medical Research. 2021;49(7): doi:10.1177 /0300060521
1019879
9. Falagario UG, Martini A, Wajswol E, et al. Avoiding
Unnecessary Magnetic Resonance Imaging (MRI) and
Biopsies: Negative and Positive Predictive Value of MRI
According to Prostate-specific Antigen Density, 4Kscore and
Risk Calculators. Eur Urol Oncol 2020; 3: 700–704.
10. Lee, J., Yang, S.W., Jin, L. et al. Is PSA density of the peripheral
zone as a useful predictor for prostate cancer in patients with
gray zone PSA levels? BMC Cancer 21, 472 (2021). https://doi
.org/10.1186/s12885-021-08216-6
11. Falagario UG, Jambor I, Lantz A, et al. Combined Use of
Prostate-specific Antigen Density and Magnetic Resonance
Imaging for Prostate Biopsy Decision Planning: A
Retrospective Multi-Institutional Study Using the Prostate
Magnetic Resonance Imaging Outcome Database (PROMOD).
Eur Urol Oncol 2020: S2588-9311(20):30142-5.
12. Ferro M, De Cobelli O, Lucarelli G, et al. Beyond PSA: The
Role of Prostate Health Index (phi). Int J Mol Sci 2020; 21:
1184.
13. Guo ZF, Lu XW, Yang F, et al. Significance of prostate central
gland/total gland volume ratio combined with PSA in the
diagnosis of prostate cancer patients. Zhonghua Yi Xue Za
Zhi 2019; 99: 2836–2839
14. Baratloo A, Hosseini M, Negida A, El Ashal G. Part 1: Simple
Definition and Calculation of Accuracy, Sensitivity and
Specificity. Emerg (Tehran). 2015;3(2):48-9
15. Castro HAS, Iared W, Santos JEM, Solha RS, Shigueoka DC,
Ajzen SA. Impact of PSA density of transition zone as a
potential parameter in reducing the number of unnecessary
prostate biopsies in patients with psa levels between 2.6 and
10.0 ng/mL. Int Braz J Urol. 2018;44(4):709-716. doi:
10.1590/S1677-5538.IBJU.2017.0506.
16. Wu B, Shao Y, Lin X, Hasi C, Jia W, Wang D, Cao X.
Comparisons of the diagnostic accuracy across prostate health
index, prostate health index density, and percentage free
prostate-specific antigen for clinically significant prostate
cancer: a prospective diagnostic study. Transl Androl Urol.
2023;12(3):425-432. doi: 10.21037/tau-23-80. Epub 2023
Mar 28.
17. Chen H, Qian Y, Wu Y, et al. Modified Prostate Health Index
Density Significantly Improves Clinically Significant Prostate
Cancer (csPCa) Detection. Front Oncol 2022; 12:864111.
10.3389/fonc.2022.864111
18. Zhang L, Zhang J, Tang M, et al. MRI-Based Radiomics
Nomogram for Predicting Prostate Cancer with Gray-Zone
Prostate-Specific Antigen Levels to Reduce Unnecessary
Biopsies. Diagnostics (Basel) 2022; 12:3005. 10.3390/
diagnostics12123005
19. Alijaj N, Pavlovic B, Martel P, et al. Identification of Urine
Biomarkers to Improve Eligibility for Prostate Biopsy and
Detect High-Grade Prostate Cancer. Cancers (Basel) 2022;
14:1135. 10.3390/cancers14051135
20. Castro HAS, Iared W, Santos JEM, Solha RS, Shigueoka DC,
Ajzen SA. Impact of PSA density of transition zone as a
potential parameter in reducing the number of unnecessary
prostate biopsies in patients with PSA levels between 2.6 and
10.0 ng/mL. Int Braz J Urol. 2018; 44:709–716.
21. Vukovic I, Djordjevic D, Bojanic N, Babic U, Soldatovic I.
Predictive value of [-2] propsa (p2psa) and its derivatives for
the prostate cancer detection in the 2.0 to 10.0ng/mL PSA
range. Int Braz J Urol. 2017; 43:48–56.
22. European Association of Urology. EAU guidelines on prostate
cancer, https://uroweb.org/guideline/prostate-cancer/ (2019)
23. Liu, J., Dong, B., Qu, W. et al. Using clinical parameters to
predict prostate cancer and reduce the unnecessary biopsy
among patients with PSA in the gray zone. Sci Rep 10, 5157
(2020). https://doi.org/10.1038/s41598-020-62015-w
24. Ding Z, Wu H, Song D, Tian H, Ye X, Liang W, Jiao Y, Hu
J, Xu J, Dong F. Development and validation of a nomogram
for predicting prostate cancer in men with prostate-specific
antigen grey zone based on retrospective analysis of clinical
and multi-parameter magnetic resonance imaging/transrectal
ultrasound fusion-derived data. Transl Androl Urol.
2020;9(5):2179-2191. doi: 10.21037/tau-20-1154
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Syed Atif Hussain, Rukhsana Tumrani, Afsheen Nigar, Anber Rahim, Mahnoor Chaudhry, Seerat Fatima Tu Zahra
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Journal of Bahria University Medical & Dental College is an open access journal and is licensed under CC BY-NC 4.0. which permits unrestricted non commercial use, distribution and reproduction in any medium, provided the original work is properly cited. To view a copy of this license, visit https://creativecommons.org/licenses/by-nc/4.0 
Deprecated: json_decode(): Passing null to parameter #1 ($json) of type string is deprecated in /home/u735751794/domains/bahria.edu.pk/public_html/ojs_jbumdc/plugins/generic/citations/CitationsPlugin.inc.php on line 49
